Fennec Pharmaceuticals Inc.FENC

$9.06+0.08 (+0.89%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$322M

Small-cap

+106%

2017 — today

10-Year Price

-18%

2017 — today

52-Week Range

$5.77$9.98

Current $9.06· 78%

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Valuation in context

P/E ratio

-29.5

N/A

Not meaningful — company is unprofitable

P/B ratio

8.5

Above average

Pricier than usual over the last 10 years

FCF Yield

-1.8%

Historically high

Historically high relative to the last 10 years

Free · No credit card needed

Get alerted when FENC is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.